Corporate News

Gerresheimer increases third-quarter revenues

  • Revenues up 2.2% to EUR 323.9m (+3.2% at constant exchange rates)
  • Adjusted EBITDA with slight improvement on prior-year quarter at EUR 62.1m
  • Net income slightly over prior-year level at EUR 19.8m
  • Adjusted earnings per share exactly match prior-year quarter, at EUR 0.67
  • Outlook for financial year 2014 made more specific

Duesseldorf, October 8, 2014—Gerresheimer AG again increased revenues in the third quarter of financial year 2014. “Our products continue to enjoy high demand. We saw solid growth in the third quarter, although growth was a little bit slower than previously expected. For this reason, we are making our outlook for 2014 more specific. We will continue to invest in growth projects and expand our production capacities worldwide,” said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG. As one of the leading partners to the pharma and healthcare industry worldwide, Gerresheimer AG develops and produces glass and plastic packaging for drugs and cosmetics along with complex drug delivery products such as insulin pens, asthma inhalers and prefillable syringes.

Gerresheimer again increased revenues in the third quarter of financial year 2014 (December 1, 2013 to November 30, 2014). Revenues came to EUR 323.9m, representing growth of 2.2%. At constant exchange rates, revenues grew by 3.2% compared with the prior-year quarter. The main driver of revenue growth was the pharmaceutical plastic packaging business as well as the engineering and tooling business, which typically precedes mass production of medical plastic systems such as insulin pens and asthma inhalers. Revenues in the prefillable syringe system business increased slightly, as did laboratory glassware revenues. Glass primary packaging took a revenue hit, primarily due to destocking by some of the US pharmaceuticals customers. In addition, less pharmaceutical glass was delivered in the US in the third quarter given that regulatory requirements forced some pharmaceutical companies to endure production halts.

Gerresheimer improved adjusted EBITDA slightly, from EUR 61.6m in the prior-year quarter to EUR 62.1m in the third quarter of 2014. The adjusted EBITDA margin was 19.2% in the third quarter, slightly below the 19.4% margin in the comparative period. Net income for the third quarter totaled EUR 19.8m, slightly higher than the figure of EUR 19.5m for the same period of the prior year. Adjusted earnings per share were EUR 0.67 in the third quarter, as in the prior-year quarter.

The Gerresheimer Group’s capital expenditure in the third quarter of 2014 came to EUR 22.4m. Capital expenditure continued to focus on adding production capacity for medical plastic systems such as insulin pens and inhalers in Horšovský Týn, Czech Republic, and Peachtree City, USA.

Outlook

Despite a more difficult market environment for Gerresheimer pharmaceutical customers in the US and potential further limitations on revenue growth for customers targeting the Eastern European market, Gerresheimer anticipates revenue growth of around 4% at constant exchange rates for financial year 2014. Gerresheimer expects adjusted EBITDA for financial year 2014 to be between EUR 255m and EUR 258m at constant exchange rates. Capital expenditure in financial year 2014 will, as before, represent some 9% to 10% of exchange rate adjusted revenues.

Gerresheimer will be holding a Capital Markets Day for analysts and investors on October 8 and 9. CEO Uwe Röhrhoff’s strategy presentation will be transmitted via the Internet on October 8, 2014 starting at 4:00 p.m. To access the presentation, please go to: www.gerresheimer.com/investor-relations

The Interim Report is available at: http://www.gerresheimer.com/en/investor-relations/reports.html

The Annual Report 2013 is available here: http://annualreport2013.gerresheimer.com

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products the company contributes to health and well-being. Gerresheimer has worldwide operations and its 11,000 employees manufacture products in local markets, close to its customers. With over 40 plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of approximately EUR 1.3 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe and simple administration of medicines: Insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Group Key Figures (Financial Year end November 30)

Group Key Figures (Financial Year end November 30)
Please click to enlarge

Group Key Figures (Financial Year end November 30)

Group Key Figures (Financial Year end November 30)
Please click to enlarge

Contact